I checked back and didn't see this shared, we're number 3 of 4.  

https://investingnews.com/daily/life-science-investing/biotech-investing/top-biotech-stocks-tsx/

Apologies if this is a repeat:

3. Resverlogix (TSX:RVX)

Market cap: $416.26 million; year-to-date percentage gain: 22.22 percent; current share price: $2.36

Developing apabetalone (RVX-208), which is a small molecule selective BET inhibitor—a mechanism that regulates disease-causing genes—Resverlogix is working through clinical trials to prove it may help patients with range of diseases, including: cardiovascular disease, diabetes mellitus, chronic kidney disease and more.

In June, the company announced the FDA confirmed, if successful, its BETonMACE Phase 3 trial would support the approval of a new drug application. The specific indication is yet to be sought by the company and reviewed by the regulatory agency.

Earlier in the same month, Resverlogix released it’s seeking a partnership with an existing stakeholder based on recent findings with apabetalone’s potential role in HIV.